吡格列酮和二甲双胍治疗Ⅱ型糖尿病的临床疗效及安全性  

The curative efficiency and security of pioglitazone and metformin on treating type 2 diabetes

作　　者：付翔[1] 刘富春[1] 李志红[1] 

机构地区：[1]解放军第324医院药剂科,重庆江北400020

出　　处：《西部医学》2015年第7期1078-1080,共3页Medical Journal of West China

摘　　要：目的比较吡格列酮与二甲双胍治疗Ⅱ型糖尿病的临床疗效和安全性。方法选取120例接受治疗的Ⅱ型糖尿病患者并随机分为吡格列酮组60例和二甲双胍组60例,两组分别给予吡格列酮和二甲双胍治疗,记录对比两组患者的治疗有效率、不良反应发生率和不良反应评分,评估有效性及安全性。结果吡格列酮组患者的治疗有效率(90.00%)与二甲双胍组患者(95.00%)相近,两组患者的数据差异无统计学意义(P>0.05)。吡格列酮组患者的不良反应评分(54.3±2.9)高于二甲双胍组(20.3±3.2);吡格列酮组患者的不良反应发生率(35.00%)高于二甲双胍组(13.33%);两组患者的数据差异均有统计学意义(P<0.05)。结论吡格列酮和二甲双胍治疗Ⅱ型糖尿病的临床疗效相近,均可用于临床治疗,但二甲双胍安全性更高。Objectives To research and compare the curative efficiency and security of pioglitazone and metformin on treating type 2diabetes.Methods 120 type 2diabetes patients were randomly divided into treatment group（60cases）and metformin group（60cases）.They were treated with pioglitazone and metformin.Their treatment efficiency,the incidence of adverse reactions and adverse reaction score were evaluated.Results Treatment efficiency of patients with pioglitazone group（90%）and patients in the metformin group（95%）were similar.The differences between the two groups were not statistically significant（P〉0.05）.The adverse reaction of pioglitazone group（54.3±2.9）was higher than the score of the metformin group（20.3±3.2）.The incidence of adverse reactions in patients with pioglitazone group（35%）was higher than that of metformin group（13.33%）（P〈0.05）.Conclusion Pioglitazone and metformin has similar clinical curative efficiency in treatment of type 2diabetes,but metformin＇s safety is high.

关 键 词：吡格列酮 二甲双胍 Ⅱ型糖尿病 疗效 安全性 

分 类 号：R587.1[医药卫生—内分泌]